Maruta Yasuhiro, Kuwata Takeo, Tanaka Kazuki, Alam Muntasir, Valdez Kristel Paola Ramirez, Egami Yoshika, Suwa Yoshiaki, Morioka Hiroshi, Matsushita Shuzo
Matsushita Project Laboratory, Center for AIDS Research, Kumamoto University.
Jpn J Infect Dis. 2016 Sep 21;69(5):395-404. doi: 10.7883/yoken.JJID.2015.667. Epub 2016 Feb 19.
The V3 loop in the envelope (Env) of HIV-1 is one of the major targets of neutralizing antibodies. However, this antigen is hidden inside the Env trimer in most isolates and is fully exposed only during CD4-gp120 interaction. Thus, primary HIV-1 isolates are relatively resistant to anti-V3 antibodies because IgG is too large to access the V3 loop. To overcome this obstacle, we constructed single-chain variable fragments (scFvs) from anti-V3 monoclonal antibodies 0.5γ, 5G2, and 16G6. Enhanced neutralization by 0.5γ and 5G2 scFvs was observed in strains resistant to their IgG counterparts. Neutralization coverage by 0.5γ scFv reached up to 90% of the tested viruses (tier 2 and 3 classes). The temperature-regulated neutralization assay revealed that extensive cross-neutralization of 0.5γ scFv can be explained by post-attachment neutralization. Neutralization assay involving viruses carrying an inter-subunit disulfide bond (SOS virus) showed that the neutralization-susceptible timeframe after attachment was 60 to 120 min. These results indicate that the scFvs efficiently access the V3 loop and subsequently neutralize HIV-1, even after virus attachment to the target cells. Based on its broad and potent neutralizing activity, further development of anti-V3 scFv for therapeutic and preventive strategies is warranted.
HIV-1包膜糖蛋白(Env)的V3环是中和抗体的主要靶点之一。然而,在大多数分离株中,该抗原隐藏在Env三聚体内部,仅在CD4与gp120相互作用时才完全暴露。因此,HIV-1原代分离株对抗V3抗体相对耐药,因为IgG太大而无法接近V3环。为克服这一障碍,我们用抗V3单克隆抗体0.5γ、5G2和16G6构建了单链可变片段(scFv)。在对其IgG对应物耐药的毒株中观察到0.5γ和5G2 scFv增强了中和作用。0.5γ scFv的中和覆盖率达到所测试病毒(2级和3级类别)的90%。温度调节中和试验表明,0.5γ scFv的广泛交叉中和作用可通过附着后中和来解释。涉及携带亚基间二硫键病毒(SOS病毒)的中和试验表明,附着后中和敏感的时间范围为60至120分钟。这些结果表明,即使在病毒附着于靶细胞后,scFv也能有效接近V3环并随后中和HIV-1。基于其广泛而有效的中和活性,有必要进一步开发用于治疗和预防策略的抗V3 scFv。